Norges Bank’s Enliven Therapeutics ELVN Stock Holding History

Norges Bank’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10,000	Closed	-$641K	–	2084
2020 Q1	$641K	Buy	+10,000	New	+$637K	﹤0.01%	2003

Other funds holding ELVN

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank's ELVN Position: Q2 2020 in Review

Norges Bank sold out of Enliven Therapeutics (ELVN) in Q2 2020, closing a stake of 10,000 shares — an estimated $641K sold.

Norges Bank first reported a position in ELVN in Q1 2020 and held it in 1 quarter. The position peaked at $641K in Q1 2020. 34 funds tracked by Wall St. Rank hold ELVN as of Q2 2020.

Norges Bank reported no remaining Enliven Therapeutics position as of Q2 2020 after selling out during the quarter.
Norges Bank sold 10,000 Enliven Therapeutics shares in Q2 2020, an estimated $641K.
Norges Bank first reported a position in Enliven Therapeutics in Q1 2020 and held it in 1 quarter.
Norges Bank's Enliven Therapeutics position peaked at $641K in Q1 2020.
34 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2020.

Based on Norges Bank's 13F filing for Q2 2020, filed 7 Aug 2020.